Compare MFM & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFM | VYGR |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.2M | 232.4M |
| IPO Year | N/A | 2015 |
| Metric | MFM | VYGR |
|---|---|---|
| Price | $5.42 | $4.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.17 |
| AVG Volume (30 Days) | 108.1K | ★ 492.4K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | $176.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.37 | $2.65 |
| 52 Week High | $5.48 | $6.69 |
| Indicator | MFM | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 51.16 |
| Support Level | $5.31 | $3.74 |
| Resistance Level | $5.47 | $4.44 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 63.64 | 75.18 |
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.